<- Go Home
Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Market Cap
$220.4M
Volume
557.9K
Cash and Equivalents
$3.4M
EBITDA
-$168.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$71.5M
Profit Margin
N/A
52 Week High
$13.60
52 Week Low
$3.00
Dividend
N/A
Price / Book Value
-1.21
Price / Earnings
-1.21
Price / Tangible Book Value
-1.21
Enterprise Value
$553.5M
Enterprise Value / EBITDA
-3.46
Operating Income
-$169.3M
Return on Equity
175.95%
Return on Assets
-32.28
Cash and Short Term Investments
$90.1M
Debt
$423.3M
Equity
-$182.6M
Revenue
N/A
Unlevered FCF
-$100.1M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium